Engineered immune cells that modulate receptor expression

Abstract

The present disclosure provides engineered immune cells and methods for their creation and use. The immune cells comprise activating and blocking receptors, and binding of the blocking receptors to cognate ligands causes reduced surface expression of the activating receptors.

Description

TECHNICAL FIELD[0001]The present disclosure relates to engineered immune cells that have an enhanced safety profile and large therapeutic window.SEQUENCE LISTING[0002]The present application is being filed with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled A2TH-001-01US-Sequence-Listing.txt, created on Sep. 20, 2021 and is 404 kilobytes in size. The information in electronic format of the Sequence Listing is incorporated by reference in its entirety.BACKGROUND[0003]Approximately 1.8 million people per year are diagnosed with a form of cancer in the United States. Similarly, it is estimated that 23.5 million Americans suffer from an autoimmune disease, almost all of which decrease life expectancy. Despite continual advances in treatment, education, and detection, there are over 600,000 deaths per year attributed to cancer in the U.S., while autoimmune diseases remain a leading cause of death among patients under the age 65.[0004]Engineer...

AI Technical Summary

Benefits of technology

[0103]In certain aspects of the disclosure, the hinge comprises a peptide having a degree of flexibility, and the peptide's degree of flexibility modulates the effect of the blocking signal on the activating signal. The peptide may be a flexible peptide and the effect of the blocking signal on the activating signal is an increased inhibition of the activating signal. The flexible peptide may comprise glyc

Problems solved by technology

However, in vivo, these results are rarely duplicated.

Often, these treatments show a lack of eff

Images